During the past decade, Raleigh Hematology Oncology Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 12 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Raleigh Hematology Oncology Associates" #1 sponsor was "Dendreon" with 3 trials, followed by "US Oncology Research" with 3 trials sponsored, "Abbott" with 2 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Eisai Inc." with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Raleigh Hematology Oncology Associates" #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator, "Aventis Pharmaceuticals" with 1 trials as a collaborator, "Eisai Limited" with 1 trials as a collaborator and "US Oncology Research" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Raleigh Hematology Oncology Associates" are "Prostate Cancer" (5 trials), "Metastatic Breast Cancer" (3 trials), "Kidney Neoplasms" (2 trials), "Non-small Cell Lung Cancer" (2 trials) and "Advanced Breast Cancer" (1 trials). Many other conditions were trialed in "Raleigh Hematology Oncology Associates" in a lesser frequency.

Most popular intervention types in "Raleigh Hematology Oncology Associates" are "Drug" (23 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Prednisone" (3 trials), "Axitinib (AG-013736)" (2 trials), "Bortezomib" (2 trials), "Ixabepilone" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Raleigh Hematology Oncology Associates" are 17 trials for "All" genders, 7 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Raleigh Hematology Oncology Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Raleigh Hematology Oncology Associates, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Raleigh Hematology Oncology Associates, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".